PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcmedgenoBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Medical Genomics
 
BMC Med Genomics. 2012; 5: 37.
Published online Aug 23, 2012. doi:  10.1186/1755-8794-5-37
PMCID: PMC3483163
Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines
Hemant Kulkarni,corresponding author1 Harald H H Göring,1 Vincent Diego,1 Shelley Cole,1 Ken R Walder,2 Greg R Collier,3 John Blangero,1 and Melanie A Carlesscorresponding author1
1Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA
2Deakin University, Geelong, VIC, Australia
3Barwon Biotechnology, Geelong, VIC, Australia
corresponding authorCorresponding author.
Hemant Kulkarni: hkulkarn/at/txbiomedgenetics.org; Harald H H Göring: hgoring/at/txbiomedgenetics.org; Vincent Diego: vdiego/at/txbiomedgenetics.org; Shelley Cole: scole/at/txbiomedgenetics.org; Ken R Walder: ken.walder/at/deakin.edu.au; Greg R Collier: gcollier/at/barwonbiotech.com; John Blangero: john/at/txbiomedgenetics.org; Melanie A Carless: mcarless/at/txbiomedgenetics.org
Received March 22, 2012; Accepted August 16, 2012.
Abstract
Background
Imatinib mesylate is currently the drug of choice to treat chronic myeloid leukemia. However, patient resistance and cytotoxicity make secondary lines of treatment, such as omacetaxine mepesuccinate, a necessity. Given that drug cytotoxicity represents a major problem during treatment, it is essential to understand the biological pathways affected to better predict poor drug response and prioritize a treatment regime.
Methods
We conducted cell viability and gene expression assays to determine heritability and gene expression changes associated with imatinib and omacetaxine treatment of 55 non-cancerous lymphoblastoid cell lines, derived from 17 pedigrees. In total, 48,803 transcripts derived from Illumina Human WG-6 BeadChips were analyzed for each sample using SOLAR, whilst correcting for kinship structure.
Results
Cytotoxicity within cell lines was highly heritable following imatinib treatment (h2 = 0.60-0.73), but not omacetaxine treatment. Cell lines treated with an IC20 dose of imatinib or omacetaxine showed differential gene expression for 956 (1.96%) and 3,892 transcripts (7.97%), respectively; 395 of these (0.8%) were significantly influenced by both imatinib and omacetaxine treatment. k-means clustering and DAVID functional annotation showed expression changes in genes related to kinase binding and vacuole-related functions following imatinib treatment, whilst expression changes in genes related to cell division and apoptosis were evident following treatment with omacetaxine. The enrichment scores for these ontologies were very high (mostly >10).
Conclusions
Induction of gene expression changes related to different pathways following imatinib and omacetaxine treatment suggests that the cytotoxicity of such drugs may be differentially tolerated by individuals based on their genetic background.
Keywords: Chronic myeloid leukemia, Microarray, Toxicity, Gene expression, Imatinib, Omacetaxine
Articles from BMC Medical Genomics are provided here courtesy of
BioMed Central